JAK1 抑制与炎症性肠病。
JAK1 inhibition and inflammatory bowel disease.
机构信息
Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
出版信息
Rheumatology (Oxford). 2021 May 5;60(Supple 2):ii45-ii51. doi: 10.1093/rheumatology/keaa896.
Abstract
Primary non-response and secondary loss of response remain a significant issue with the currently available treatment options for a significant proportion of patients with inflammatory bowel disease (IBD). There are multiple unmet needs in the IBD treatment algorithm and new treatment options are required. As our understanding of the pathogenesis of IBD evolves, new therapeutic targets are being identified. The JAK-STAT pathway has been extensively studied. Tofacitinib, a JAK1 inhibitor, is now licensed for use in the induction and maintenance of ulcerative colitis and there are a large number of molecules currently under investigation. These new small molecule drugs (SMDs) will challenge current treatment pathways at a time when clinical therapeutic outcomes are rapidly evolving and becoming more ambitious. This is a review of the current JAK1 inhibitors in IBD including the current evidence from clinical trials.
摘要
原发性无应答和继发性应答丧失仍然是炎症性肠病（IBD）患者中相当一部分患者目前可用治疗方案的一个重大问题。IBD 治疗方案存在多种未满足的需求，需要新的治疗选择。随着我们对 IBD 发病机制的理解不断发展，新的治疗靶点正在被确定。JAK-STAT 通路已被广泛研究。JAK1 抑制剂托法替布现已获准用于溃疡性结肠炎的诱导和维持治疗，目前有大量分子正在研究中。这些新的小分子药物（SMD）将在临床治疗效果迅速发展并变得更加雄心勃勃的时候，挑战当前的治疗途径。本文综述了 IBD 中的当前 JAK1 抑制剂，包括临床试验的现有证据。
相似文献
1
JAK1 inhibition and inflammatory bowel disease.JAK1 抑制与炎症性肠病。
Rheumatology (Oxford). 2021 May 5;60(Supple 2):ii45-ii51. doi: 10.1093/rheumatology/keaa896.
2
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.Janus 激酶抑制剂在炎症性肠病中的临床药理学。
J Crohns Colitis. 2020 Aug 1;14(Supplement_2):S725-S736. doi: 10.1093/ecco-jcc/jjaa014.
3
The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.Janus 激酶抑制剂治疗炎症性肠病的时代。
Int J Mol Sci. 2021 Oct 20;22(21):11322. doi: 10.3390/ijms222111322.
4
Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.Janus 激酶抑制剂在炎症性肠病患者肠系膜淋巴结细胞中差异抑制特定细胞因子信号。
J Crohns Colitis. 2024 Apr 23;18(4):628-637. doi: 10.1093/ecco-jcc/jjad173.
5
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.Janus 激酶抑制剂治疗类风湿关节炎的体外细胞因子受体抑制作用具有相似特征。
Pharmacol Res Perspect. 2019 Nov 15;7(6):e00537. doi: 10.1002/prp2.537. eCollection 2019 Dec.
6
JAK selectivity: more precision less troubles.JAK 选择性：更精准，更少烦恼。
Expert Rev Gastroenterol Hepatol. 2020 Sep;14(9):789-796. doi: 10.1080/17474124.2020.1780120. Epub 2020 Jun 16.
7
JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease.JAK 抑制剂：在炎症性肠病治疗策略中的应用现状。
Curr Opin Pharmacol. 2020 Dec;55:99-109. doi: 10.1016/j.coph.2020.10.010. Epub 2020 Nov 15.
8
Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease.JAK-STAT 通路的治疗性抑制在炎症性肠病治疗中的作用。
Cytokine Growth Factor Rev. 2024 Oct;79:1-15. doi: 10.1016/j.cytogfr.2024.07.008. Epub 2024 Aug 3.
9
Innovations in Oral Therapies for Inflammatory Bowel Disease.炎症性肠病的口腔治疗新进展。
Drugs. 2019 Aug;79(12):1321-1335. doi: 10.1007/s40265-019-01169-y.
10
Efficacy of JAK inhibitors in Crohn's Disease.JAK抑制剂在克罗恩病中的疗效
J Crohns Colitis. 2020 Aug 1;14(Supplement_2):S746-S754. doi: 10.1093/ecco-jcc/jjz186.
引用本文的文献
1
A bibliometric and visual analysis of Jak1 to explore trends and frontiers.对Jak1进行文献计量与可视化分析以探究趋势和前沿。
Front Oncol. 2025 Jul 17;15:1537508. doi: 10.3389/fonc.2025.1537508. eCollection 2025.
2
Exploring the molecular mechanism of Si-Miao-Yong-An Decoction in treating diabetic foot using network pharmacological analysis and molecular docking technique.运用网络药理学分析和分子对接技术探索四妙勇安汤治疗糖尿病足的分子机制。
Medicine (Baltimore). 2025 May 30;104(22):e42629. doi: 10.1097/MD.0000000000042629.
3
State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review.中度至重度溃疡性结肠炎中 Janus 激酶抑制剂的临床结局与治疗意义的最新证据：一项叙述性综述
Pharmaceuticals (Basel). 2025 May 17;18(5):740. doi: 10.3390/ph18050740.
4
T helper cell 17/regulatory T cell balance regulates ulcerative colitis and the therapeutic role of natural plant components: a review.辅助性T细胞17/调节性T细胞平衡调控溃疡性结肠炎及天然植物成分的治疗作用：综述
Front Med (Lausanne). 2025 Mar 24;11:1502849. doi: 10.3389/fmed.2024.1502849. eCollection 2024.
5
Horizon scanning: new and future therapies in the management of inflammatory bowel disease.前沿扫描：炎症性肠病管理中的新疗法与未来疗法
eGastroenterology. 2023 Oct 27;1(2):e100012. doi: 10.1136/egastro-2023-100012. eCollection 2023 Sep.
6
Role of Aging in Ulcerative Colitis Pathogenesis: A Focus on ETS1 as a Promising Biomarker.衰老在溃疡性结肠炎发病机制中的作用：聚焦ETS1作为一种有前景的生物标志物
J Inflamm Res. 2025 Feb 6;18:1839-1853. doi: 10.2147/JIR.S504040. eCollection 2025.
7
Raising the bar in ulcerative colitis management.提高溃疡性结肠炎的治疗标准。
Therap Adv Gastroenterol. 2024 Nov 24;17:17562848241273066. doi: 10.1177/17562848241273066. eCollection 2024.
8
JAK inhibitors: an evidence-based choice of the most appropriate molecule.JAK抑制剂：基于证据的最合适分子的选择。
Front Pharmacol. 2024 Oct 29;15:1494901. doi: 10.3389/fphar.2024.1494901. eCollection 2024.
9
Tofacitinib for ulcerative colitis: A promising treatment option.托法替布治疗溃疡性结肠炎：一种有前景的治疗选择。
World J Gastroenterol. 2024 Oct 28;30(40):4386-4392. doi: 10.3748/wjg.v30.i40.4386.
10
Near Sequence Homology Does Not Guarantee siRNA Cross-Species Efficacy.近序列同源性并不能保证 siRNA 的跨物种功效。
Nucleic Acid Ther. 2024 Oct;34(5):234-244. doi: 10.1089/nat.2024.0030. Epub 2024 Aug 27.
本文引用的文献
1
Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.中度至重度溃疡性结肠炎患者的基线肠外表现及托法替布的疗效
Therap Adv Gastroenterol. 2021 May 16;14:17562848211005708. doi: 10.1177/17562848211005708. eCollection 2021.
2
Emerging treatment options for extraintestinal manifestations in IBD.炎症性肠病肠外表现的新兴治疗选择。
Gut. 2021 Apr;70(4):796-802. doi: 10.1136/gutjnl-2020-322129. Epub 2020 Aug 26.
3
Tofacitinib in Acute Severe Ulcerative Colitis-A Real-World Tertiary Center Experience.托法替布治疗急性重症溃疡性结肠炎——一家三级医疗中心的真实世界经验
Inflamm Bowel Dis. 2020 Oct 23;26(11):e147-e149. doi: 10.1093/ibd/izaa157.
4
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme.用于溃疡性结肠炎的肠道选择性泛 Janus 激酶抑制剂 TD-1473 的研发：一项转化医学计划。
J Crohns Colitis. 2020 Sep 16;14(9):1202-1213. doi: 10.1093/ecco-jcc/jjaa049.
5
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.乌帕替尼在活动性溃疡性结肠炎患者随机试验中的疗效。
Gastroenterology. 2020 Jun;158(8):2139-2149.e14. doi: 10.1053/j.gastro.2020.02.030. Epub 2020 Feb 22.
6
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.乌帕替尼在克罗恩病患者随机试验中的疗效和安全性。
Gastroenterology. 2020 Jun;158(8):2123-2138.e8. doi: 10.1053/j.gastro.2020.01.047. Epub 2020 Feb 8.
7
Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.托法替尼治疗急性重度溃疡性结肠炎的补救治疗：真实世界经验。
J Crohns Colitis. 2020 Jul 30;14(7):1026-1028. doi: 10.1093/ecco-jcc/jjaa018.
8
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.托法替尼溃疡性结肠炎临床开发项目中的静脉血栓栓塞事件。
Aliment Pharmacol Ther. 2019 Nov;50(10):1068-1076. doi: 10.1111/apt.15514. Epub 2019 Oct 9.
9
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).乌帕替尼（ABT-494）对JAK1选择性的体外和体内特性研究
BMC Rheumatol. 2018 Aug 28;2:23. doi: 10.1186/s41927-018-0031-x. eCollection 2018.
10
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.抗 TNF 初治活动期腔型克罗恩病患者抗 TNF 治疗失败的预测因素：一项前瞻性、多中心、队列研究。
Lancet Gastroenterol Hepatol. 2019 May;4(5):341-353. doi: 10.1016/S2468-1253(19)30012-3. Epub 2019 Feb 27.
Zotero 插件